Skip to content
    VRTX
    Earnings call· Jun 2025(Q2 FY25)

    VERTEX PHARMACEUTICALS INC / MA Q2 FY25 earnings call VRTX

    Aug 4, 2025 Source

    Executive summary

    Vertex Pharmaceuticals Q2 FY25 — Strong Revenue Growth and Pipeline Advancement

    Vertex Pharmaceuticals delivered strong Q2 FY25 results, driven by 12% revenue growth and successful launches of ALYFTREK and JOURNAVX, alongside building global momentum for CASGEVY. The company is rapidly advancing its late-stage pipeline, with multiple pivotal studies underway and regulatory submissions anticipated in 2026 and 2027. While facing regulatory hurdles for a broad PNP label and a clinical setback for VX-993 monotherapy in acute pain, Vertex remains focused on expanding patient reach and diversifying its therapeutic portfolio.

    Highlights

    5

    • Delivered $2.96 billion in revenue in Q2 FY25, representing 12% growth versus Q2 2024.

    • U.S. revenue growth of 14% year-over-year, driven by CF, CASGEVY, and JOURNAVX.

    • CASGEVY launch building momentum with nearly 250 patients referred, approximately 115 cell collections, and 29 infusions completed since launch, including 16 infusions in Q2 FY25.

    • JOURNAVX achieved payer coverage for approximately 150 million lives (half of all covered lives in the U.S.) by mid-July, with 84 million having unrestricted access.

    • Advanced 4 programs in pivotal development and on track to initiate a fifth in primary membranous nephropathy, with multiple regulatory submissions expected in 2026 and early 2027.

    Concerns

    4

    • FDA does not currently see a path to a broad peripheral neuropathic pain (PNP) label for Suzetrigine, leading to a focus on diabetic peripheral neuropathy (DPN) first.

    • VX-993 did not meet the primary endpoint in the Phase II post-bunionectomy setting and will not be advanced as monotherapy in acute pain.

    • JOURNAVX gross-to-net is elevated in early launch months due to patient support programs, though expected to normalize.

    • NOPAIN Act draft proposal did not include JOURNAVX due to a misunderstanding of its indication for postsurgical pain.

    Guidance & targets

    12
    CategoryTargetConfidence
    Full-year 2025 Total Revenue
    $11.85 billion to $12 billion
    high materiality
    High
    Full-year 2025 Non-GAAP R&D, Acquired IPR&D and SG&A Expenses
    $4.9 billion to $5 billion (expecting high end)
    high materiality
    High
    Full-year 2025 Non-GAAP Effective Tax Rate
    20.5% to 21.5%
    medium materiality
    High
    Suzetrigine DPN Phase III Trials Enrollment Completion
    Complete enrollment of both trials
    high materiality
    High
    VX-828 Regimen in CF
    Initiate a cohort of people with CF
    medium materiality
    High
    Zimislecel Type 1 Diabetes Regulatory Submissions
    Global regulatory submissions
    high materiality
    High
    Povetacicept IgAN RAINIER Study Enrollment Completion
    Complete enrollment of the full RAINIER study
    high materiality
    High
    Povetacicept IgAN Accelerated Approval Filing (U.S.)
    File for potential accelerated approval
    high materiality
    High
    Povetacicept Primary Membranous Nephropathy (PMN) Phase II/III Study
    Begin Phase II/III study
    medium materiality
    High
    Inaxaplin AMKD AMPLITUDE Interim Analysis Cohort Enrollment
    Complete enrollment in the interim analysis cohort
    high materiality
    High
    Inaxaplin AMKD AMPLIFIED Study Enrollment
    Complete enrollment
    medium materiality
    High
    VX-407 ADPKD Proof-of-Concept Trial
    Begin proof-of-concept trial
    medium materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    CASGEVY
    Global launch building momentum, with acceleration in patient initiations, cell collections, and infusions in Q2. Access secured in 10 countries including US, Europe, and Middle East.
    Patients referred: nearly 250First cell collections: approximately 115Infusions completed: 29 total, 16 in Q2 2025Authorized Treatment Centers (ATCs): more than 75 globallyCountries with access: 10
    		$30 million———
    JOURNAVX
    Launched in March, seeing positive reaction as a novel non-opioid option. Rapid pace of payer coverage, formulary adoption, and hospital uptake. Increased commercial investment planned for H2 2025.
    Payer coverage: approximately 150 million lives (half of US covered lives) by mid-JulyUnrestricted access: 84 million livesNational PBM coverage: 2 of 3 large national PBMs, 3rd anticipated before year-endHospital GPO agreements: 2 largest national GPOsHospitals with formulary adoption: ~500 of 2,000 targeted hospitalsPrescriptions filled: more than 110,000 by mid-JulyPrescribing physicians: ~15,000
    		$12 million———
    Collaboration Revenue
    Included in total revenue.
    		$21 million———

    Operational metrics

    28
    Total Revenue Growth
    12%YoY
    Q2 FY25

    Driven by multiple new product launches and diversification.

    US Revenue Growth
    14%YoY
    Q2 FY25

    Driven by CF, CASGEVY, JOURNAVX, and collaboration revenue.

    Ex-US Revenue Growth
    8%YoY
    Q2 FY25

    Rebounded this quarter, including healthy CF growth and CASGEVY contribution.

    Non-GAAP Operating Expenses
    $1.24 billionvs $5.43 billion in Q2 2024
    Q2 FY25

    Increase driven by pipeline advancement and commercial capabilities build-out.

    Acquired IPR&D Expenses
    $2 millionvs $4.4 billion in Q2 2024
    Q2 FY25

    Q2 2024 included the acquisition of Alpine Immune Sciences.

    Non-GAAP Operating Income
    $1.33 billionvs non-GAAP operating loss of $3.15 billion in Q2 2024
    Q2 FY25

    Primarily due to higher revenue and disciplined operating spend.

    Non-GAAP Effective Tax Rate
    19.4%
    Q2 FY25
    Non-GAAP EPS
    $4.52vs loss per share of $12.83 in Q2 2024
    Q2 FY25

    Primarily due to higher revenue, disciplined operating spend, and impact of Alpine IPR&D expense in Q2 2024.

    Cash and Investments Balance
    $12 billion
    Q2 FY25

    After deploying $395 million to repurchase shares.

    Share Repurchase Program Authorization (New)
    $4 billionbuilding upon existing $3 billion program
    May 2025

    Announced in May.

    Share Repurchase Program Authorization (Remaining)
    $570 million
    as of June 30

    Part of program authorized in 2023.

    Shares Repurchased
    865,000
    Q2 FY25

    Part of share repurchase program.

    JOURNAVX Payer Covered Lives
    150 millionapproximately half of all covered lives in the U. S.
    mid-July

    Across commercial and government payers.

    JOURNAVX Unrestricted Access Lives
    84 million
    mid-July

    Every negotiated contract is for unrestricted access.

    JOURNAVX Prescriptions Filled
    110,000
    mid-July

    Successfully filled.

    JOURNAVX Prescribing Physicians
    15,000hundreds more each week
    current

    Broad range of specialties.

    JOURNAVX Prescription Split
    65%
    current

    Remainder in hospital space.

    CASGEVY Authorized Treatment Centers
    75+met our goal
    since launch and through Q2 2025

    Dosing patients in multiple regions.

    CASGEVY Patient Referrals
    250
    since launch and through Q2 2025
    CASGEVY First Cell Collections
    11535 in Q2 2025
    since launch and through Q2 2025
    CASGEVY Infusions Completed
    2916 in Q2 2025
    since launch and through Q2 2025
    CASGEVY Cycle Time (Cell Collection to Infusion)
    4-5 months
    current

    Opportunity for improvement, easier for TDT patients.

    ALYFTREK Royalty Burden
    meaningfully lowerthan TRIKAFTA
    current

    Extends composition of matter patent protection to 2039.

    ALYFTREK Patent Protection Expiry
    2039
    current

    Composition of matter patent.

    Zimislecel Potential Patient Population
    60,000
    future

    May potentially benefit from the first zimislecel submission.

    VX-407 ADPKD Eligible Patient Population
    10%
    current

    Believes about 10% of patients with ADPKD may be eligible for treatment.

    VX-407 ADPKD PoC Trial Size
    24
    current

    Will evaluate efficacy by height-adjusted total kidney volume.

    JOURNAVX Gross-to-Net
    —elevated
    early months of launch

    Elevated due to patient support programs; expected to normalize as payer coverage expands.

    Industry KPIs

    7
    MetricValueDetails
    Launch access metrics150 million liveslives
    Pipeline read out calendarMultiple pivotal studies ongoing
    Regulatory approvals filingsALYFTREK approved in US, UK, EU, Canada
    Prescription volume new startsMore than 110,000 prescriptionsprescriptions
    Clinical trial efficacy safety dataZimislecel: 12 patients with 1+ year follow-up achieved target A1c <7%, freedom from severe hypoglycemic events, >70% time in range.
    Collaboration milestone royalty revenue$21 millionUSD
    Cumulative patients uptake since launch29 patientspatients

    Risks & headwinds

    6
    FDA does not see a path to a broad Peripheral Neuropathic Pain (PNP) label for Suzetrigine.at this time

    at this time, the FDA does not see a path to a broad indication

    Mitigation: Focus on securing Diabetic Peripheral Neuropathy (DPN) as the first indication, initiating a second DPN Phase III study, and continuing discussions with the FDA for label expansion and a broad PNP pathway, potentially with NaV1.7 + NaV1.8 portfolio.

    VX-993 did not meet primary endpoint in Phase II post-bunionectomy setting.Q2 FY25

    did not meet the primary endpoint and did not show statistical significance at the 0.05 level

    Mitigation: Will not advance VX-993 as monotherapy in acute pain; will complete ongoing VX-993 study of DPN to further define exposure-response relationship and maximal efficacy in chronic pain.

    Elevated gross-to-net for JOURNAVX in early launch months.early months of launch

    elevated in the early months of the launch

    Mitigation: Patient support programs will fall away as payer coverage expands, leading to normalization of gross-to-net over the course of the year.

    JOURNAVX not included in NOPAIN Act draft rule.draft rule published about a month ago

    JOURNAVX was not included in the draft rule

    Mitigation: Vertex expects to resolve the confusion regarding JOURNAVX's indication for postsurgical pain and anticipates its inclusion in the final list due this fall.

    Potential for revenue variability for CASGEVY.quarter-to-quarter

    there may be revenue variability from quarter-to-quarter

    Mitigation: Timing of infusions is predicated on patient scheduling choices, but high visibility into CASGEVY revenue given patient initiations and cell collections continue to ramp.

    Immaterial cost impact from tariffs in 2025, but subject to change.2025

    immaterial cost impact

    Mitigation: Significant U.S. presence and geographically diverse supply chain. Acknowledges dynamic nature of tariff situation.

    What to watch in Q3 FY25

    5

    JOURNAVX NOPAIN Act inclusion

    this fall
    CurrentNot included in draft rule
    TargetIncluded in final list

    Why it matters

    Inclusion in the NOPAIN Act would support reimbursement and access for JOURNAVX, impacting its commercial trajectory.

    Clearly, JOURNAVX is indicated for postsurgical pain. Indeed, both Phase III RCTs were in postsurgical pain... I think we're going to be able to get this confusion resolved. And I do expect that JOURNAVX will be on the final list, which is due this fall.

    Q&A highlights

    7

    Was the increased JOURNAVX commercial investment planned, or a reaction to launch performance? And will the first Suzetrigine DPN Phase III enroll faster than the second?

    The increased JOURNAVX investment is a reaction to positive payer coverage, physician/patient feedback, and promotional responsiveness. The first DPN trial is expected to enroll ahead of the second.

    “Yes, we are thinking that now is the right time to augment our spend in marketing and field support, although I would add the last comment that we do anticipate that field support would still sit within the specialty model.”

    asked by Jessica Fye · answered by Duncan McKechnie

    2 min read6 chapters

    Detailed Narrative

    01

    Leadership Transition in R&D

    David Altshuler, CSO, will retire on August 1, 2026, after 13 years with Vertex. Mark Bunnage, current SVP and Head of Global Research, will assume the role of EVP and CSO effective February 1, 2026, ensuring a smooth transition. Mark has been with Vertex since 2016 and has been instrumental in advancing multiple molecules to the clinic, including CASGEVY and JOURNAVX.

    02

    CF Franchise Expansion and Next-Gen Development

    ALYFTREK has gained approval in the U.S., U.K., EU, and Canada, with reimbursement secured in England, Germany, and Denmark, and efforts underway for other regions. Vertex is developing the Next-Gen 3.0 regimen, with VX-828 as its backbone, aiming to initiate a CF patient cohort by year-end. The VX-522 trial for patients not benefiting from CFTR modulators is resuming dosing in the near term after DSMC endorsement.

    03

    Strategic Adjustments in Pain Portfolio

    Following FDA feedback, Vertex will prioritize securing a DPN indication for Suzetrigine by initiating a second Phase III study, targeting enrollment completion by end of 2026. A broad PNP label remains a long-term goal, potentially through ongoing discussions and the NaV1.7 + NaV1.8 portfolio. VX-993 monotherapy in acute pain will not be advanced due to lack of statistical significance in its Phase II study, but its DPN study will continue to define exposure-response relationships.

    04

    Advancements in Type 1 Diabetes Program

    Zimislecel is nearing completion of pivotal study enrollment, with global regulatory submissions targeted for 2026, potentially benefiting 60,000 severe type 1 diabetic patients. Positive data from the ADA meeting showed 12 patients achieved target A1c levels, freedom from severe hypoglycemic events, and over 70% time in range, with 10 of 12 patients insulin-free at 12 months. Preclinical efforts continue on immune-cloaking approaches for these cells.

    05

    Broadening Kidney Disease Pipeline

    Vertex has clinical programs in 4 kidney diseases. Povetacicept (pove) for IgA nephropathy (IgAN) is on track to complete full RAINIER study enrollment by year-end, with potential for accelerated approval filing in H1 2026. A Phase II/III study for pove in primary membranous nephropathy (PMN) will begin later this year. Inaxaplin for AMKD is on track to complete interim analysis cohort enrollment this year, with a Phase II study for AMKD with comorbidities also underway. VX-407 for ADPKD will begin its proof-of-concept trial this quarter.

    06

    Prioritization of Povetacicept Indications

    Based on emerging data, patient impact, treatment landscape, and commercial opportunity, Vertex is prioritizing IgAN, membranous nephropathy, generalized myasthenia gravis (gMG), and warm autoimmune hemolytic anemia (wAIHA) for pove. The gMG program is ready for pivotal program discussions with the FDA, and wAIHA awaits final data by year-end. Other indications for pove are being deprioritized at this time.

    AI-generated summary of the company’s earnings call. Not investment advice.